FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4252262884> ?p ?o ?g. }

• W4252262884 endingPage "5824" @default.
• W4252262884 startingPage "5824" @default.
• W4252262884 abstract "Abstract CONTEXT: Cytomegalovirus reactivation (R-CMV) is often diagnosed in allogeneic hematopoietic cell transplant recipients and could determine a CMV-related disease in these immunocompromised patients, involving any organ. R-CMV and end-organ disease after ASCT has not been studied thoroughly. Autograft recipients are generally considered to have low risk of R-CMV or end-organ disease. OBJECTIVE: Evaluate the incidence, risk factors, and outcome of R-CMV in adult patients with hematologic malignancies undergoing ASCT. DESIGN: Retrospective single center study. SETTING: This study was approved by the institutional review board of AUBMC and conducted at our institution PATIENTS OR OTHER PARTICIPANTS: A total of 324 consecutive ASCT were performed at AUBMC between January 2005 and March 2016. All patients and transplant-related characteristics are listed on Table 1. CMV DNA load in blood was measured by quantitative polymerase chain reaction (PCR) weekly as a routine monitoring strategy in all patients. Irrespective of PCR results, some patients suspected to have gastrointestinal involvement were biopsied. Also, in the presence of symptomatic CMV reactivation, appropriate anti-CMV therapy was instituted. MAIN OUTCOMES MEASURES: The primary outcome is understanding the potential relationship between R-CMV and Overall Survival (OS). Secondary outcomes included the effect of CMV reactivation on transplant related mortality (TRM), and progression free survival (PFS). RESULTS: Overall, 53 (16%) patients had R-CMV and 38 (72%) required anti-CMV treatment. Five (1,5%) had CMV disease with positive PCR on colon biopsy, yet two had PCR negative in blood. After a median follow up of 21.5 months (range: 1 to 125 months), there was no significant difference in OS or PFS between patients with or without R-CMV. TRM has increased from 1.1% in patients with no R-CMV to 13% in patients with R-CMV (P=0.003). We didn't observe any impact for age, sex, type of disease, pre-transplant treatment types/lines on the incidence R-CMV following ASCT. CONCLUSIONS: Our data suggest that R-CMV is not uncommon in ASCT recipients and may contribute to increased TRM. Biopsy is recommended in case of high suspicion of R-CMV irrespective of PCR results. Disclosures No relevant conflicts of interest to declare." @default.
• W4252262884 created "2022-05-12" @default.
• W4252262884 creator A5009374192 @default.
• W4252262884 creator A5013525031 @default.
• W4252262884 creator A5017327825 @default.
• W4252262884 creator A5022819705 @default.
• W4252262884 creator A5026768259 @default.
• W4252262884 creator A5032701156 @default.
• W4252262884 creator A5032928140 @default.
• W4252262884 creator A5045416630 @default.
• W4252262884 creator A5048650165 @default.
• W4252262884 creator A5069285537 @default.
• W4252262884 date "2016-12-02" @default.
• W4252262884 modified "2023-09-27" @default.
• W4252262884 title "Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: A Single-Center Study at the American University of Beirut Medical Center (AUBMC)" @default.
• W4252262884 doi "https://doi.org/10.1182/blood.v128.22.5824.5824" @default.
• W4252262884 hasPublicationYear "2016" @default.
• W4252262884 type Work @default.
• W4252262884 citedByCount "0" @default.
• W4252262884 crossrefType "journal-article" @default.
• W4252262884 hasAuthorship W4252262884A5009374192 @default.
• W4252262884 hasAuthorship W4252262884A5013525031 @default.
• W4252262884 hasAuthorship W4252262884A5017327825 @default.
• W4252262884 hasAuthorship W4252262884A5022819705 @default.
• W4252262884 hasAuthorship W4252262884A5026768259 @default.
• W4252262884 hasAuthorship W4252262884A5032701156 @default.
• W4252262884 hasAuthorship W4252262884A5032928140 @default.
• W4252262884 hasAuthorship W4252262884A5045416630 @default.
• W4252262884 hasAuthorship W4252262884A5048650165 @default.
• W4252262884 hasAuthorship W4252262884A5069285537 @default.
• W4252262884 hasConcept C120665830 @default.
• W4252262884 hasConcept C121332964 @default.
• W4252262884 hasConcept C126322002 @default.
• W4252262884 hasConcept C142462285 @default.
• W4252262884 hasConcept C151730666 @default.
• W4252262884 hasConcept C203014093 @default.
• W4252262884 hasConcept C2522874641 @default.
• W4252262884 hasConcept C2776364478 @default.
• W4252262884 hasConcept C2776409557 @default.
• W4252262884 hasConcept C2777408962 @default.
• W4252262884 hasConcept C2777732132 @default.
• W4252262884 hasConcept C2779050716 @default.
• W4252262884 hasConcept C2779338263 @default.
• W4252262884 hasConcept C2779343474 @default.
• W4252262884 hasConcept C2780073493 @default.
• W4252262884 hasConcept C2780727368 @default.
• W4252262884 hasConcept C2911091166 @default.
• W4252262884 hasConcept C3013748606 @default.
• W4252262884 hasConcept C61511704 @default.
• W4252262884 hasConcept C71924100 @default.
• W4252262884 hasConcept C86803240 @default.
• W4252262884 hasConcept C90924648 @default.
• W4252262884 hasConceptScore W4252262884C120665830 @default.
• W4252262884 hasConceptScore W4252262884C121332964 @default.
• W4252262884 hasConceptScore W4252262884C126322002 @default.
• W4252262884 hasConceptScore W4252262884C142462285 @default.
• W4252262884 hasConceptScore W4252262884C151730666 @default.
• W4252262884 hasConceptScore W4252262884C203014093 @default.
• W4252262884 hasConceptScore W4252262884C2522874641 @default.
• W4252262884 hasConceptScore W4252262884C2776364478 @default.
• W4252262884 hasConceptScore W4252262884C2776409557 @default.
• W4252262884 hasConceptScore W4252262884C2777408962 @default.
• W4252262884 hasConceptScore W4252262884C2777732132 @default.
• W4252262884 hasConceptScore W4252262884C2779050716 @default.
• W4252262884 hasConceptScore W4252262884C2779338263 @default.
• W4252262884 hasConceptScore W4252262884C2779343474 @default.
• W4252262884 hasConceptScore W4252262884C2780073493 @default.
• W4252262884 hasConceptScore W4252262884C2780727368 @default.
• W4252262884 hasConceptScore W4252262884C2911091166 @default.
• W4252262884 hasConceptScore W4252262884C3013748606 @default.
• W4252262884 hasConceptScore W4252262884C61511704 @default.
• W4252262884 hasConceptScore W4252262884C71924100 @default.
• W4252262884 hasConceptScore W4252262884C86803240 @default.
• W4252262884 hasConceptScore W4252262884C90924648 @default.
• W4252262884 hasIssue "22" @default.
• W4252262884 hasLocation W42522628841 @default.
• W4252262884 hasOpenAccess W4252262884 @default.
• W4252262884 hasPrimaryLocation W42522628841 @default.
• W4252262884 hasRelatedWork W2027173317 @default.
• W4252262884 hasRelatedWork W2074649719 @default.
• W4252262884 hasRelatedWork W2075400856 @default.
• W4252262884 hasRelatedWork W2353124159 @default.
• W4252262884 hasRelatedWork W2754714035 @default.
• W4252262884 hasRelatedWork W2973381785 @default.
• W4252262884 hasRelatedWork W2996494612 @default.
• W4252262884 hasRelatedWork W3024590051 @default.
• W4252262884 hasRelatedWork W3031694499 @default.
• W4252262884 hasRelatedWork W4223959395 @default.
• W4252262884 hasVolume "128" @default.
• W4252262884 isParatext "false" @default.
• W4252262884 isRetracted "false" @default.
• W4252262884 workType "article" @default.